An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability

Neuroblastoma (NB) is often driven by MYCN amplification. Here, the authors show that the most frequent genetic lesion, gain of 17q21-ter in NB leads to overexpression of ALYREF, which forms a complex with MYCN, regulating MYCN stability via the deubiquitinating enzyme, USP3.

Guardado en:
Detalles Bibliográficos
Autores principales: Zsuzsanna Nagy, Janith A. Seneviratne, Maxwell Kanikevich, William Chang, Chelsea Mayoh, Pooja Venkat, Yanhua Du, Cizhong Jiang, Alice Salib, Jessica Koach, Daniel R. Carter, Rituparna Mittra, Tao Liu, Michael W. Parker, Belamy B. Cheung, Glenn M. Marshall
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9758c1cb40dc42078fa4de67f4245a4d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Neuroblastoma (NB) is often driven by MYCN amplification. Here, the authors show that the most frequent genetic lesion, gain of 17q21-ter in NB leads to overexpression of ALYREF, which forms a complex with MYCN, regulating MYCN stability via the deubiquitinating enzyme, USP3.

Ejemplares similares